| Dr Hagop Kojanian, MD | |
|
100 Industrial Park Rd, Suite 2., Taunton, MA 02780-7395 | |
| (508) 822-2266 | |
| Not Available |
| Full Name | Dr Hagop Kojanian |
|---|---|
| Gender | Male |
| Speciality | Endocrinology |
| Experience | 19 Years |
| Location | 100 Industrial Park Rd, Taunton, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982837738 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 254503 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Morton Hospital | Taunton, MA | Hospital |
| Good Samaritan Medical Center | Brockton, MA | Hospital |
| Norwood Hospital | Norwood, MA | Hospital |
| Saint Anne's Hospital | Fall river, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Steward Medical Group Inc | 2860688728 | 1404 |
News Archive
The Obama administration's surprise announcement Friday that it planned to give states broad leeway to pick the benefits offered under the federal health care law offers yet another example of a gradualist approach to carrying out its signal domestic policy achievement.
Vitamin D deficiency was an indicator of aggressive prostate cancer and spread of the disease in European-American and African-American men who underwent their first prostate biopsy because of abnormal prostate-specific antigen (PSA) and/or digital rectal examination (DRE) test results, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
A team of researchers at the University of Alberta, including a scientist at the University of Pennsylvania, have discovered a gene that is able to block HIV, and thought to in turn prevent the onset of AIDS.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.
Pharmasset, Inc. announced today that the interim results from the PROPEL study conducted by its partner Roche demonstrate that RG7128 triple combination therapy was safe and well tolerated. In that study, the safety profile of RG7128 (1000mg BID or 500mg BID), when administered for 8 or 12 weeks with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin), the standard of care, was similar to the safety profile of SOC alone.
› Verified 3 days ago
| Entity Name | Steward Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629398219 PECOS PAC ID: 2860688728 Enrollment ID: O20101119000332 |
News Archive
The Obama administration's surprise announcement Friday that it planned to give states broad leeway to pick the benefits offered under the federal health care law offers yet another example of a gradualist approach to carrying out its signal domestic policy achievement.
Vitamin D deficiency was an indicator of aggressive prostate cancer and spread of the disease in European-American and African-American men who underwent their first prostate biopsy because of abnormal prostate-specific antigen (PSA) and/or digital rectal examination (DRE) test results, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
A team of researchers at the University of Alberta, including a scientist at the University of Pennsylvania, have discovered a gene that is able to block HIV, and thought to in turn prevent the onset of AIDS.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.
Pharmasset, Inc. announced today that the interim results from the PROPEL study conducted by its partner Roche demonstrate that RG7128 triple combination therapy was safe and well tolerated. In that study, the safety profile of RG7128 (1000mg BID or 500mg BID), when administered for 8 or 12 weeks with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin), the standard of care, was similar to the safety profile of SOC alone.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Hagop Kojanian, MD 100 Industrial Park Rd, Suite 2., Taunton, MA 02780-7395 Ph: (508) 822-2266 | Dr Hagop Kojanian, MD 100 Industrial Park Rd, Suite 2., Taunton, MA 02780-7395 Ph: (508) 822-2266 |
News Archive
The Obama administration's surprise announcement Friday that it planned to give states broad leeway to pick the benefits offered under the federal health care law offers yet another example of a gradualist approach to carrying out its signal domestic policy achievement.
Vitamin D deficiency was an indicator of aggressive prostate cancer and spread of the disease in European-American and African-American men who underwent their first prostate biopsy because of abnormal prostate-specific antigen (PSA) and/or digital rectal examination (DRE) test results, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
A team of researchers at the University of Alberta, including a scientist at the University of Pennsylvania, have discovered a gene that is able to block HIV, and thought to in turn prevent the onset of AIDS.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.
Pharmasset, Inc. announced today that the interim results from the PROPEL study conducted by its partner Roche demonstrate that RG7128 triple combination therapy was safe and well tolerated. In that study, the safety profile of RG7128 (1000mg BID or 500mg BID), when administered for 8 or 12 weeks with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin), the standard of care, was similar to the safety profile of SOC alone.
› Verified 3 days ago
Priti A Patel, MD Endocrinology, Diabetes & Metabolism Medicare: May Accept Medicare Assignments Practice Location: 233 Winthrop Street, Taunton, MA 02780 Phone: 508-880-0070 Fax: 508-880-2989 | |
Robert J Mcnamee, M.D. Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 72 Washington St, Suite 1300, Taunton, MA 02780 Phone: 508-824-5865 Fax: 508-823-9108 | |
Kabir Chuttani, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 72 Washington St, Suite 1400-1700, Taunton, MA 02780 Phone: 508-880-0077 Fax: 508-880-5247 | |
Yun Xia, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 100 Industrial Park Rd, Suite 1, Taunton, MA 02780 Phone: 508-822-2266 Fax: 508-823-5689 | |
Cristina Cellurale, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 91 Washington St Unit 301, Taunton, MA 02780 Phone: 508-824-5865 Fax: 508-823-9108 | |
Khalid A Zaalook, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: Morton Hospital & Medical Center, 88 Washington Street, Taunton, MA 02780 Phone: 508-828-7293 | |
Yelena Levin, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 152 Dean St, Taunton, MA 02780 Phone: 508-824-3872 Fax: 508-828-4925 |